Gene editing to turn on fetal hemoglobin for sickle cell disease

Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease

NIH-funded research St. Jude Children's Research Hospital · NIH-11166450

The team edits a person's own blood stem cells with CRISPR to restart fetal hemoglobin production and help adults with sickle cell disease.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11166450 on NIH RePORTER

What this research studies

Your own blood stem cells would be collected and edited with CRISPR/Cas9 to disrupt a switch so your red blood cells make fetal hemoglobin again. Lab work showed very high on-target editing and much more fetal hemoglobin in red cells, which greatly reduced sickling in preclinical tests. The researchers will refine the process, check thoroughly for unintended edits, and build the steps needed to bring this into patient treatment. If successful, the edited cells would be returned to your body to produce healthier red blood cells over time.

Who could benefit from this research

Good fit: Adults (age 21 and over) with sickle cell disease who are able to undergo stem cell collection and transplant procedures would be the ideal candidates.

Not a fit: Children under 21, people unable to tolerate stem cell mobilization/collection or transplant conditioning, or those with severe organ failure may not be eligible or likely to benefit.

Why it matters

Potential benefit: This could markedly reduce red blood cell sickling, pain crises, and organ damage and might offer a one-time curative option by increasing protective fetal hemoglobin.

How similar studies have performed: Other CRISPR-based editing of hematopoietic stem cells to raise fetal hemoglobin has produced promising early clinical results, though long-term outcomes remain under study.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.